Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Accelerating antiviral drug discovery: lessons from COVID-19
Annette von Delft, Matthew D. Hall, Ann D. Kwong, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 585-603
Open Access | Times Cited: 82

Showing 26-50 of 82 citing articles:

Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity
Christian Gege, Friedrich Hahn, Christina Wangen, et al.
ChemMedChem (2024) Vol. 19, Iss. 19
Open Access | Times Cited: 2
Efficacy and safety of ivermectin for treatment of non-hospitalized COVID-19 patients: A systematic review and meta-analysis of 12 randomized controlled trials with 7,035 participants
Adrían V. Hernández, Anna Liu, Yuani M. Roman, et al.
International Journal of Antimicrobial Agents (2024) Vol. 64, Iss. 2, pp. 107248-107248
Closed Access | Times Cited: 2
More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5-a]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus Replication
Han Wee Ong, Xuan Yang, Jeffery L. Smith, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 14, pp. 12261-12313
Open Access | Times Cited: 2
Discovery of potent SARS-CoV-2 nsp3 macrodomain inhibitors uncovers lack of translation to cellular antiviral response
Alpha A. Lee, Isabelle Amick, Jasmin C. Aschenbrenner, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
A community effort in SARS‐CoV‐2 drug discovery
Johannes Schimunek, Philipp Seidl, Katarina Elez, et al.
Molecular Informatics (2023) Vol. 43, Iss. 1
Open Access | Times Cited: 7
Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171
H Zhang, Jing Zhou, Hong Chen, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 68, Iss. 1
Open Access | Times Cited: 7
An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic
Edi Dharmana, Juliane Brun, Michelle L. Hill, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 354-354
Open Access | Times Cited: 7
Discovery of new antiviral agents through artificial intelligence: In vitro and in vivo results
Roza Izmailyan, Mher Matevosyan, Hamlet Khachatryan, et al.
Antiviral Research (2024) Vol. 222, pp. 105818-105818
Closed Access | Times Cited: 1
Identification of Dual Inhibitors Targeting Main Protease (Mpro) and Cathepsin L as Potential Anti-SARS-CoV-2 Agents
Santo Previti, Roberta Ettari, Elsa Calcaterra, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 5, pp. 602-609
Closed Access | Times Cited: 1
Favipiravir Treatment Prolongs Survival in a Lethal BALB/c Mouse Model of Ebinur Lake Virus Infection
Jingke Geng, Nanjie Ren, Cihan Yang, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 631-631
Open Access | Times Cited: 1
Inhibition of SARS-CoV-2 Nsp9 ssDNA-Binding Activity and Cytotoxic Effects on H838, H1975, and A549 Human Non-Small Cell Lung Cancer Cells: Exploring the Potential of Nepenthes miranda Leaf Extract for Pulmonary Disease Treatment
Hsing-Hui Su, En‐Shyh Lin, Yen‐Hua Huang, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6120-6120
Open Access | Times Cited: 1
Unveiling potential inhibitors targeting the nucleocapsid protein of SARS-CoV-2: Structural insights into their binding sites
Shweta Kumari, Hiral Mistry, Subhash C. Bihani, et al.
International Journal of Biological Macromolecules (2024) Vol. 273, pp. 133167-133167
Closed Access | Times Cited: 1
Discovery of a novel inhibitor of macropinocytosis with antiviral activity
Bartłomiej Porębski, Wanda Christ, Alba Corman, et al.
Molecular Therapy (2024) Vol. 32, Iss. 9, pp. 3012-3024
Open Access | Times Cited: 1
A Repurposed Drug Interferes with Nucleic Acid to Inhibit the Dual Activities of Coronavirus Nsp13
Nathan Soper, Isabelle Yardumian, Eric Chen, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 7, pp. 1593-1603
Open Access | Times Cited: 1
Using real-world data to accelerate the search for long COVID therapies
Shira R. Strongin, Elisabeth Stelson, Letícia Soares, et al.
Life Sciences (2024) Vol. 353, pp. 122940-122940
Closed Access | Times Cited: 1
Biopolymer-based coating materials for antiviral and antifungal applications: Recent advances in formulations and characterization
Zarin Tasnim Juthi, Mahe Jabeen, Md. Reazul Islam, et al.
Chemical Engineering Journal (2024) Vol. 498, pp. 155000-155000
Closed Access | Times Cited: 1
Asymmetric imidazole-4,5-dicarboxamides derivatives as SARS-CoV-2 main protease inhibitors: Design, Synthesis and Biological Evaluation
P. Huynh, Phatcharin Khamplong, Minh-Hoang Phan, et al.
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 1
Global Challenges After a Global Challenge: Lessons Learned from the COVID-19 Pandemic
Niloufar Yazdanpanah, Constantine Sedikides, Hans D. Ochs, et al.
Advances in experimental medicine and biology (2024), pp. 1-31
Closed Access | Times Cited: 1
Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon
Amol D. Gholap, Pankaj R. Khuspe, Sagar R. Pardeshi, et al.
Advanced Therapeutics (2024)
Open Access | Times Cited: 1
The Chemical Space Spanned by Manually Curated Datasets of Natural and Synthetic Compounds with Activities against SARS‐CoV‐2
Jude Y. Betow, Gemma Turón, Clovis S. Metuge, et al.
Molecular Informatics (2024)
Closed Access | Times Cited: 1
Advances and Challenges in Antiviral Development for Respiratory Viruses
Luis Adrián De Jesús‐González, Moisés León‐Juárez, Flor Itzel Lira-Hernández, et al.
Pathogens (2024) Vol. 14, Iss. 1, pp. 20-20
Open Access | Times Cited: 1
Membrane-Targeting Perylenylethynylphenols Inactivate Medically Important Coronaviruses via the Singlet Oxygen Photogeneration Mechanism
Kseniya A. Mariewskaya, Daniil A. Gvozdev, Alexey A. Chistov, et al.
Molecules (2023) Vol. 28, Iss. 17, pp. 6278-6278
Open Access | Times Cited: 4
Design, synthesis, and structure-activity relationships of a novel class of quinazoline derivatives as coronavirus inhibitors
Shengchao Zhou, Kun Wang, Ziwei Hu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115831-115831
Closed Access | Times Cited: 4
Type 1 Diabetes and COVID-19: A Literature Review and Possible Management
Kebria Kashfi, Narges Anbardar, Artin Asadipooya, et al.
International Journal of Endocrinology and Metabolism (2023) Vol. 21, Iss. 4
Open Access | Times Cited: 4
Learning from COVID-19: How drug hunters can prepare for the next pandemic
Ana C. Puhl, Thomas R. Lane, Sean Ekins
Drug Discovery Today (2023) Vol. 28, Iss. 10, pp. 103723-103723
Open Access | Times Cited: 3

Scroll to top